Reported 2 days ago
Glaukos Corporation (GKOS) is preparing for the market launch of its eye treatment Epioxa, with Stifel maintaining a Buy rating and a $115 price target ahead of the October 20 PDUFA date. A recent survey of ophthalmologists indicates strong projected uptake for Epioxa, suggesting it will quickly dominate corneal cross-linking procedures and drive market growth. This positive outlook alleviates previous concerns about CXL patient warehousing, leading to increased revenue expectations for Corneal Health in the upcoming years.
Source: YAHOO